Computer design of bioactive molecules: A method for receptor‐based de novo ligand design

The design of molecules to bind specifically to protein receptors has long been a goal of computer‐assisted molecular design. Given detailed structural knowledge of the target receptor, it should be possible to construct a model of a potential ligand, by algorithmic connection of small molecular fragments, that will exhibit the desired structural and electrostatic complementarity with the receptor. However, progress in this area of receptorbased, de novo ligand design has been hampered by the complexity of the construction process, in which potentially huge numbers of structures must be considered. By limiting the scope of the structure‐space examined to one particular class of ligands–namely, peptides and peptide‐like compounds–the problem complexity has been reduced to the point that successful, de novo design is now possible. The methodology presented employs a large template set of amino acid conformations which are iteratively pieced together in a model of the target receptor. Each stage of ligand growth is evaluated according to a molecular mechanicsbased energy function, which considers van der Waals and coulombic interactions, internal strain energy of the lengtheining ligand, and desolvation of both ligand and receptor. The search space is managed by use of a data tree which is kept under control by pruning according to the energy evaluation. Ligands grown by this procedure are subjected to follow‐up evaluation in which an approximate binding enthalpy is determined. This methodology has proven useful as a precise model‐builder and has also shown the ability to design bioactive ligands.

[1]  D. Decamp,et al.  Calcium‐free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2 , 1991, Proteins.

[2]  Garland R. Marshall,et al.  The Conformational Parameter in Drug Design: The Active Analog Approach , 1979 .

[3]  R. Sheridan,et al.  New methods in computer-aided drug design , 1987 .

[4]  H. Scheraga,et al.  Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Tomasselli,et al.  A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.

[6]  Richard A. Lewis,et al.  Automated site-directed drug design : the formation of molecular templates in primary structure generation , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[7]  P. Willett,et al.  Pharmacophoric pattern matching in files of 3d chemical structures: comparison of geometric searching algorithms , 1987 .

[8]  R. Shoeman,et al.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[9]  U. Singh,et al.  A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .

[10]  R. Sheridan,et al.  Searching for pharmacophores in large coordinate data bases and its use in drug design. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. D. Gelatt,et al.  Optimization by Simulated Annealing , 1983, Science.

[12]  P M Dean,et al.  Automated site-directed drug design : the prediction and observation of ligand point positions at hydrogen-bonding regions on protein surfaces , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[13]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[14]  D. Decamp,et al.  Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. , 1990, The Journal of biological chemistry.

[15]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[16]  A. Tomasselli,et al.  Ribonuclease A as a substrate of the protease from human immunodeficiency virus-1. , 1990, The Journal of biological chemistry.

[17]  Yvonne C. Martin,et al.  ALADDIN: An integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures , 1989, J. Comput. Aided Mol. Des..

[18]  W. C. Still,et al.  A rapid approximation to the solvent accessible surface areas of atoms , 1988 .

[19]  Dennis H. Smith,et al.  Applications of artificial intelligence for chemical inference. 37. GENOA: a computer program for structure elucidation utilizing overlapping and alternative substructures , 1981 .

[20]  A. Doweyko,et al.  The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules. , 1988, Journal of medicinal chemistry.

[21]  G M Crippen,et al.  Distance geometry analysis of the benzodiazepine binding site. , 1982, Molecular pharmacology.

[22]  I. Kuntz,et al.  Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. , 1988, Journal of medicinal chemistry.

[23]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[24]  J. Ménard,et al.  Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. , 1987, Biochimica et biophysica acta.

[25]  E. Padlan,et al.  Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Robert P. Sheridan,et al.  Designing novel nicotinic agonists by searching a database of molecular shapes , 1987, J. Comput. Aided Mol. Des..

[27]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[28]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[29]  P M Dean,et al.  Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[30]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[31]  M Karplus,et al.  Construction of a model for the three-dimensional structure of human renal renin. , 1985, Hypertension.

[32]  J M Blaney,et al.  Molecular modeling software and methods for medicinal chemistry. , 1990, Journal of medicinal chemistry.

[33]  I. Kuntz,et al.  Docking flexible ligands to macromolecular receptors by molecular shape. , 1986, Journal of medicinal chemistry.

[34]  Richard A. Lewis,et al.  Automated site-directed drug design: the concept of spacer skeletons for primary structure generation , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.